Shares of Bio-Path Holdings, Inc. (BPTH) are gaining more than 22 percent or $0.93 in Thursday’s morning trade at $5.04.
Thursday, Bio-Path said that the United States Patent and Trademark Office has issued a notice of allowance for a strategic patent for the company’s lead product candidate, Prexigebersen, in combination with either a cytidine analog such as Decitabine or Bcr-Abl tyrosine kinase inhibitors Dasatinib and Nilotinib in a variety of cancers.
Prexigebersen in combination with Decitabine is currently in a Phase 2 clinical trial as a treatment for acute myeloid leukemia.
Bio-Path has traded in a range of $2.92 to $12.54 in the past 52 weeks.
Source: Read Full Article